Business Context and Reporting Period
Company: Prothena Corporation Public Limited Company (PRTA)
Filing Type: Form 10-Q (Unaudited)
Period: Quarter ended March 31, 2026
Business Overview: Prothena is a late-stage clinical biotechnology company focused on protein dysregulation, developing therapies for neurodegenerative diseases (Parkinson's, Alzheimer's, ALS) and ATTR amyloidosis. The company operates as a single segment and relies heavily on collaborations with Roche, Bristol Myers Squibb (BMS), and Novo Nordisk.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $51,084 | $2,828 |
| Net Income (Loss) | $32,721 | $(60,195) |
| Diluted EPS | $0.60 | $(1.12) |
| Operating Cash Flow | $28,877 | $(53,363) |
| Cash and Cash Equivalents (End of Period) | $329,462 | $417,935 |
| Total Assets | $349,894 | $326,804 |
| Total Liabilities | $37,278 | $46,330 |
| Shareholders' Equity | $312,616 | $280,474 |
Material Changes vs. Prior Period
- Revenue Surge: Total revenue increased 1,706% to $51.1 million, driven primarily by a $50.0 million development milestone payment from Novo Nordisk for the advancement of coramitug in the Phase 3 CLEOPATTRA trial. Collaboration revenue from BMS decreased to $1.0 million.
- Profitability Shift: The company reported a net income of $32.7 million, a reversal from a net loss of $60.2 million in the prior year. This was due to the milestone revenue and a significant reduction in operating expenses.
- Expense Reduction: Total operating expenses dropped 69% to $21.0 million. Research and Development (R&D) expenses fell 75% to $12.6 million, largely due to the wind-down of the birtamimab and PRX012 programs and lower personnel costs.
- Restructuring: The company recorded a net reduction in restructuring liability of $4.2 million, reflecting a decrease in estimated contract termination costs.
- Share Repurchases: The company initiated a $100 million share repurchase plan in February 2026. During Q1 2026, it repurchased 788,990 shares for approximately $7.3 million.
Guidance, Outlook, and Risks
- Liquidity: Management believes cash and cash equivalents of $329.5 million are sufficient to meet obligations for at least the next 12 months. Future capital needs will be met through collaboration payments (Roche, BMS, Novo Nordisk) or additional financing.
- Clinical Pipeline Updates:
- Prasinezumab (Roche): Phase 3 PARAISO trial initiated in Q4 2025 for early Parkinson's disease. Phase 2b PADOVA data showed potential clinical effect on motor progression.
- Coramitug (Novo Nordisk): Received FDA Fast Track designation for ATTR-CM. Phase 3 CLEOPATTRA trial initiated in Q4 2025.
- BMS-986446 (BMS): Received FDA Fast Track designation for Alzheimer's disease. Phase 2 TargetTau-1 trial ongoing.
- PRX019 (BMS): Phase 1 trial ongoing.
- Risks:
- Capital Needs: The company anticipates incurring losses for the foreseeable future and may never sustain profitability without additional capital.
- Collaboration Dependence: Success is heavily dependent on partners (Roche, BMS, Novo Nordisk) to advance trials and commercialize products. Termination of these agreements would be materially adverse.
- Regulatory Uncertainty: No drug candidates have received regulatory approval; clinical trials may fail or be delayed.
- Restructuring: Ongoing costs related to the discontinuation of birtamimab and PRX012 wind-down.
Investor Verification Checklist
- Milestone Sustainability: Verify the likelihood of future milestone payments from Novo Nordisk, BMS, and Roche, as these are critical to revenue and cash flow.
- Cash Burn Rate: Confirm the projected operating cash burn excluding milestone revenue to assess the true runway for internal R&D programs.
- Restructuring Completion: Monitor the remaining $8.6 million restructuring liability and associated cash outflows.
- Share Repurchase Impact: Assess the impact of the $100 million buyback program on liquidity and future capital raising needs.
- Clinical Trial Timelines: Track the initiation and enrollment progress of the Phase 3 trials for prasinezumab and coramitug, as delays could impact future milestone triggers.